@article{e9c7d631db374a7b890c06e535ee9c32,
title = "Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial",
abstract = "Aims: Recent guidelines have advocated for stricter systolic blood pressure (SBP) control in heart failure with preserved ejection fraction (HFpEF), though data regarding the optimal SBP in HFpEF are sparse. Methods and results: We analysed participants from the Americas from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study with available baseline and 8-week visit SBP data (n = 1645). We related baseline SBP to several efficacy and safety outcomes. To determine whether blood pressure lowering was responsible for the potential beneficial effects of spironolactone observed in the Americas, we assessed the randomized treatment adjusting for baseline and change in 8-week SBP. The average age was 71.7 ± 9.7 years, 50% were women, and 79% were White. Patients in the lowest baseline SBP quartile were less often female, more often White, had lower body mass index, lower baseline diastolic blood pressure and pulse pressure, and more often had atrial fibrillation. After multivariable adjustment, there was no relationship observed between baseline SBP quartiles and any outcome. Spironolactone reduced SBP by 4.4 ± 0.6 mmHg compared with placebo (and consistently across baseline SBP quartiles). There was minimal change in the treatment effect for all outcomes after adjusting for baseline SBP and 8-week change in SBP. Conclusion: No relationship was observed between baseline SBP quartiles and outcomes in TOPCAT. The anti-hypertensive effects of spironolactone did not account for the potential benefit in cardiovascular outcomes in the Americas.",
keywords = "Blood pressure, Heart failure hospitalization, Heart failure with preserved ejection fraction, Spironolactone",
author = "Senthil Selvaraj and Brian Claggett and Shah, {Sanjiv J.} and Inder Anand and Rouleau, {Jean L.} and Desai, {Akshay S.} and Lewis, {Eldrin F.} and Bertram Pitt and Sweitzer, {Nancy K.} and Pfeffer, {Marc A.} and Solomon, {Scott D.}",
note = "Funding Information: This work was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, contract HHSN268200425207C. The content of this article does not necessarily represent the views of the National Heart, Lung, and Blood Institute or of the Department of Health and Human Services. Funding Information: Sponsor: National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD, USA (N01 HC45207). ClinicalTrials.gov identifier: NCT00094302 (http://www.clinicaltrials.gov/ct2/show/NCT00094302). Conflict of interest: J.L.R. is a consultant for Novartis, Bayer and AstraZeneca. M.A.P. has received consulting fees from Aas-trom, Abbott Vascular, Amgen, Cerenis, Concert, Daiichi Sankyo, Fibrogen, Genzyme, GlaxoSmithKline, Hamilton Health Sciences, Medtronic, Merck, Novo Nordisk, Roche, Salix, Sanderling, Sanofi-Aventis, Serono, Servier, and Teva, as well as research grants from New England Research Institute via subcontract from the National Institutes of Health, Amgen, Celladon, Novartis, and Sanofi-Aventis. The Brigham and Women{\textquoteright}s Hospital has patents for the use of inhibitors of the renin–angiotensin system in selected survivors of myocardial infarction with Novartis Pharmaceuticals Funding Information: on which M.A.P. is a coinventor. M.A.P. share of the licensing agreement is irrevocably transferred to charity. A.S.D. has received consulting fees from Novartis, Boston Scientific, Reata, Car-diomems, 5 am Ventures, Intel Corp, Coverys, and Relypsa, as well as research grants from AtCor Medical to support the Vascular Stiffness Ancillary Study to the TOPCAT trial, for which he is listed as principal investigator. E.F.L. has received research grants from the National Heart, Lung, and Blood Institute, Novartis, and Sanofi-Aventis. S.J.S. has received research grants from the American Heart Association, National Institutes of Health, Acte-lion, AstraZeneca, Corvia, and Novartis, and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Car-diora, Eisai, Gilead, Ironwood, Merck, MyoKardia, Novartis, Pfizer, Sanofi, and United Therapeutics. N.K.S. has received research grants from the National Institutes of Health. B.P. received consulting fees from Amorcyte, AstraZeneca, Aurasense, Bayer, BG Medicine, Gambro, Johnson & Johnson, Mesoblast, Novartis, Pfizer, Relypsa, and Takeda; received research grant support from Forest Laboratories; and holds stock in Aurasense, Relypsa, BG Medicine, and Aurasense. B.P. also reports a pending patent related to site-specific delivery of eplerenone to the myocardium. S.D.S. received consulting fees from Novartis and Bayer and research grants from the National Heart, Lung, and Blood Institute. The other authors report no conflicts.",
year = "2018",
month = mar,
doi = "10.1002/ejhf.1060",
language = "English (US)",
volume = "20",
pages = "483--490",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",
}